Docoh
Loading...

MDGS Medigus

Filed: 27 Aug 21, 7:30am

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2021

 

Commission File Number 001-37381

 

MEDIGUS LTD.
(Translation of registrant’s name into English)

 

Omer Industrial Park, No. 7A, P.O. Box 3030, Omer 8496500, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   __

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   __

 

 

 

 

 

 

EXPLANATORY NOTE

 

On August 27, 2021, Medigus Ltd. issued a press release titled: “Medigus: Polyrizon’s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays.” A copy of this press release is furnished herewith as Exhibit 99.1.

 

1

 

 

EXHIBIT INDEX

 

Exhibit Description
   
99.1 Press Release dated August 27, 2021

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: August 27, 2021 By:/s/ Tali Dinar
  Tali Dinar
  Chief Financial Officer

 

 

3